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each group developed atrial fibrillation, one had a CABG and seven stopped for compli-
ance reasons. Conclusions: Long term training in stable heart failure is a safe means to
improve functional capacity and autonomic dysfunction. Mean heart rate, norepinephrine
and SDNN were improved significantly,the last even more pronounced in the subgroup
with SDNN<100. The conversion of a positive TWA-test in 6 patients in the training group
could used for therapeutic intervention.
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1164-125 Development of Murine Fibrotic Cardiomyopathy Is 
Dependent on Monocyte Chemoattractant Protein 1
Oliver Dewald, Guofeng Ren, Christina Klemm, Kim Winkelmann, Anna Koerting, George 
Taffet, Lloyd H. Michael, Mark L. Entman, Nikolaos G. Frangogiannis, Baylor College of 
Medicine, Houston, TX
Background: Repetitive brief myocardial ischemia and reperfusion (I/R) is implicated in
the pathogenesis of ventricular dysfunction in ischemic cardiomyopathy and myocardial
hibernation. In a murine model of repetitive brief I/R, we reported a reversible fibrotic car-
diomyopathy in the absence of myocardial infarction, resembling the pathomorphology of
human hibernating myocardium. Much like regional dysfunction in patients, repetitive
brief murine I/R was accompanied by induction of the chemokine Monocyte Chemoat-
tractant Protein (MCP)-1. Accordingly, we examined the role of MCP-1 in the pathogene-
sis of murine cardiomyopathy.
Methods: C57/Bl6 mice undergoing daily 15 min coronary occlusions followed by reper-
fusion, received i.p. MCP-1 neutralizing antibody, or vehicle, after the end of each
ischemia episode. After echocardiographic examination, hearts were processed for histo-
logical and RNA studies.
Results: After 3-5 days of repetitive I/R, chemokine induction in ischemic hearts was
accompanied by interstitial macrophage infiltration. After 7 days of repetitive I/R, marked
interstitial fibrosis was noted in the ischemic area, accompanied by echocardiographic
evidence of global ventricular dysfunction and segmental hypocontractility of the anterior
wall. MCP-1 neutralization did not affect macrophage infiltration in the ischemic myocar-
dium, but significantly inhibited interstitial fibrosis (anterior wall, collagen-stained area,
vehicle 21.5±6.6 % vs. MCP-1 antibody 12.9±2.8 %, P<0.05). Also, MCP-1 inhibition
attenuated left ventricular dysfunction (fractional shortening, 35.1±1.2 % vs. 42.6±1.7 %,
P<0.05) and decreased regional hypocontractility (anterior wall thickening, 35.7±2.4 %
vs. 60.9±3.0 %, P<0.05). MCP-1 antibody-treated mice showed decreased expression of
the matricellular protein Osteopontin 1, a marker of tissue remodeling, after 3 days of I/R.
Conclusion: MCP-1 plays a crucial role in the pathogenesis of murine ischemic cardi-
omyopathy through effects, which appear to be independent of its leukotactic properties.
Endogenous expression of MCP-1 may be important in regulating fibrosis in patients with
ischemic cardiomyopathy.
1164-126 Characteristics of Duchenne and Becker Muscular 
Dystrophy Patients in the Pediatric Cardiomyopathy 
Registry
David Connuck, Lynn Sleeper, Jeffrey Towbin, Steven Colan, Gerald Cox, Leigha 
Cuniberti, John Orav, Bonnie Anne Salbert, Steven Lipshultz, University of Rochester, 
Rochester, NY, New England Research Institutes, Watertown, MA
Background: The NHLBI-sponsored PCMR is a multicenter study of pediatric cardiomy-
opathy (CM) in North America. Data have been collected on patients with Duchenne
(DMD) and Becker (BMD) muscular dystrophy.
Methods: As of May 2003, the Registry is comprised of 2,602 children and adolescents
who presented to a pediatric cardiologist with CM from 1990 to present. Inclusion criteria
include 1) <18.0 years at time of CM diagnosis; 2) echocardiographic evidence of CM,
defined as >2 left ventricular measurements (ejection fraction, posterior wall thickness,
septal thickness, end diastolic dimension or volume) exceeding 2 SD or an echocardio-
graphic pattern of CM; or 3) a pathologic diagnosis of CM on autopsy or endomyocardial
biopsy; or 4) other clinical evidence provided by the cardiologist.
Results: The PCMR includes 134 patients with DMD or BMD. 99% are male, 27% are
non-white. We observed 39 DMD and 1 BMD deaths; 0 DMD transplants and 6 BMD
transplants, for a total of 39 DMD and 7 BMD death/transplant events. 25% of all DMD
patients die within 2.2 years following CM diagnosis (defined as meeting PCMR entry cri-
teria) and 50% die within 5.3 years (p=.219 vs. BMD). 25% of all BMD pts die or are
transplanted within 0.4 years following CM diagnosis and 50% die or are transplanted
within 1.3 years (p=.063 vs. DMD). At diagnosis patients with BMD are somewhat more
likely (p=.143) to have mitral regurgitation (60% vs. 24%), particularly those with conges-
tive heart failure (100% vs. 40%), and a higher LV end diastolic dimension(3.0 vs. 1.3
BSA-adjusted Z-score, p=.002) than patients with DMD. Similarities between the two
groups include a mean age of CM diagnosis of 14 years, with 1/3 having congestive
heart failure at enrollment. Non-muscular dystrophy patients in the PCMR have a lower
mortality rate than the BMD/DMD group (p<0.0001).
Conclusions: Current observations suggest that the DMD/BMD groups have different
clinical characteristics at the time of CM diagnosis, with mitral regurgitation, LV dilation
and heart failure being more common in the BMD patients. Following diagnosis for CM,
DMD patients have a higher mortality rate and BMD patients may have a higher trans-
plant rate than pediatric patients with other types of CM.
1164-127 Whole Body, Myocardial, and Coronary Vascular Insulin 
Resistance in Conscious Dogs With Pacing Induced 
Dilated Cardiomyopathy
Amy Schuett, Lazaros A. Nikolaidis, Teresa Hentosz, Carol Stolarski, Aaron Doverspike, 
Rhonda Huerbin, Lee Zourelias, Richard P. Shannon, Dariush Elahi, Allegheny General 
Hospital, Pittsburgh, PA
Background: Previous work from our laboratory has demonstrated reduced basal myo-
cardial glucose uptake in conscious dogs with advanced DCM as they transition to a dec-
ompensated state. The cellular basis of the impaired glucose uptake involves impaired
GLUT-4 translocation. Our goal was to determine whether the development of insulin
resistance in DCM was limited to the myocardium or involved whole body insulin resis-
tance and whether the impaired action of insulin extended beyond its metabolic effects.
Methods: We studied 8 conscious, chronically instrumented dogs under normal fasting
circumstances before (Con) and after the development of advanced DCM induced by 4-5
weeks of rapid pacing using the hyperinsulinemic-euglycemic clamp technique (480
pmol•m-2•min-1). We measured whole body and myocardial glucose uptake and vascu-
lar and hemodynamic responses to hyperinsulinemia.
Results: The development of DCM was associated with significant (*p<0.05) increases in
plasma norepinephrine levels (Con: 125±26; DCM: 378±42 pg/ml*), plasma insulin (Con:
27±4; DCM: 72±6 pmol/L*) and NEFA (Con: 236±43; DCM: 612±59 µmol/ l*). Plasma
insulin levels were raised acutely to 1100 pmol/L and plasma glucose clamped at 5 mM
for 120 minutes. Within 30 min., NEFA fell to < 50 µmol/L in both groups. Whole body glu-
cose disposition was less in DCM (52±3 µmol•kg-1•min-1*) compared to Con (66±3
µmol•kg-1•min-1). Myocardial glucose uptake increased in both groups during hyperin-
sulinemia, but to a lesser extent in DCM (1.6 ±0.4 to 4.2±1.1 µmol/min*) than Con (2.3
±0.6 to 13.1±3.1 µmol/min). Hyperinsulinemia was associated with significant increases
in coronary blood flow in Con (20±3 to 31±5 ml*), but had no effect in DCM (20±2 to 22
±2 ml).
Conclusions: With DCM, myocardial and total peripheral glucose uptake is reduced due
to overall insulin resistance. Insulin mediated suppression of NEFA remains intact. Insulin
resistance is also evident in the impaired vascular response to hyperinsulinemia in DCM.
1164-128 Endothelial Function of the Coronary Microcirculation Is 
Impaired in Patients With Myocardial Virus Persistence
Katja B. Vallbracht, Peter L. Schwimmbeck, Uwe Kuehl, Bettina Seeberg, Heinz-Peter 
Schultheiss, Charité Medical University, Benjamin Franklin Hospital, Berlin, Germany
Background
Myocardial virus persistence can be associated with myocardial inflammation and endot-
helial activation. The aim of this study is to investigate the impact of myocardial virus per-
sistence on endothelial function (ENF) of the coronary microcirculation.
Methods
In 71 patients with suspected cardiomyopathy, myocardial biopsies were examined for
virus persistence (PCR) and inflammation (immunohistology). Endothelial function of the
coronary microcirculation was examined during heart catheterization, measuring diame-
ter (QCA) and velocity changes (intracoronary doppler) of the mid LAD in response to
locally administered acetylcholine. Coronary blood flow was calculated (CBF). Endothe-
lium independent vasoreactivity to adenosine was assessed.
Results
Mean age of the 37 male and 34 female patients was 43+-13 years, ejection fraction was
64+-11%. In 42 patients, adeno-, entero-, parvo- or HHV6-virus was detected via PCR,
29 patients had no virus. ENF of the coronary microcirculation was significantly impaired
in patients with myocardial virus persistence, as compared to controls: dCBF-V 25+-85%,
dCBF-Co 103+-118% (p=0.004). In 51 patients, myocardial inflammation was detected
by immunohistology (InfCM), of those, 31 had virus persistence, 20 had no virus. dCBF
was significantly impaired in patients with myocardial virus persistence, as compared to
controls: dCBF-InfCM-V 16+-88%, dCBF-InfCM-Co 72+-114% (p=0.101). In 20 patients,
immunohistology of the myocardial biopsies were normal (Co), of those, 11 had virus per-
sistence and 9 had no virus. dCBF was impaired in patients with myocardial virus persis-
tence, as compared to controls: dCBF-Co-V 51+-72%, dCBF-Co-Co 175+-97 (p=0.006).
Endothelium independent vasodilation was not influenced significantly.
Conclusions
Exercise group Control group
pre post pre post
VO2AT
ml/min/kg
11,5+-1,9 14,0+-2,5** 12,3+-2,7 11,9+-2,5
VO2peak
ml/min/kg
18,4+-4,5 21,7+-4,5** 18,7+-4,6 17,7+-4,3
mean HR
beats
78,6+-12,2 71,8+-11,4* 72,4+-10,3 76,5+-10,2
norepinehrine
ng/l
592,3+-336,1 431,4+-215,0* 487,1+-381,6 713,4+-487,9**
SDNN 102,4+-50,6 117,3+-37,9* 105,2+-37,0 108,2+-41,3
RMSSD 25,7+-23,4 32,3+-26,1 31,2+-29,7 27,9+-24,4
SDANN 90,2+-43,5 101,9+-35,4 90,5+-29,0 96,5+-38,2
SDNN<100 70,1+-20,0 101,0+-27,4** 75,4+-20,4 85,0+-35,1
TWA positive 15 8 / 1 id * 18 17 / 1 id
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Endothelial function of the coronary microcirculation is impaired in patients with myocar-
dial virus persistence. Endothelial dysfunction is more pronounced with concurrent myo-
cardial inflammation, but can be demonstrated in patients without myocardial
inflammation. We conclude that there is a direct interaction between myocardial virus
persistence and endothelial dysfunction.
1164-129 The Pediatric Expression of Isolated Ventricular 
Noncompaction: Clinical Characteristics, Prognosis, 
and Outcome
Rachel M. Wald, Gruschen R. Veldtman, Brian W. McCrindle, Joel A. Kirsh, Lee N. 
Benson, Hospital for Sick Children, Toronto, ON, Canada
Background: Isolated ventricular noncompaction (IVNC) is a rare form of cardiomyopa-
thy with a broad clinical spectrum that is not well defined in the pediatric population.With
improvements in imaging modalities, IVNC has emerged as an under-recognized and
important cause of pediatric cardiomyopathy. This review focuses on the clinical charac-
teristics and prognosis of IVNC and evaluates the potential determinants of outcome.
Methods: Echocardiograms were analyzed to confirm diagnosis and to measure non-
compacted:compacted segment ratio, left ventricle (LV) size, ejection fraction (EF), and
Tei index, both at presentation and at most recent visit. Medical records, electrocardio-
grams, Holter recordings and heart rate variability (HRV) data were also reviewed. 
Results: Twenty-two consecutive patients (9 male), mean age 3.86 years at diagnosis
(range birth-16 years), were studied. Heart failure (n=13) and/or arrhythmias (supraven-
tricular n=1, and ventricular n=2) were commonly seen at presentation. Initial echocardio-
graphy demonstrated systolic dysfunction in 17/22 patients (median LVEF 34%, range 6-
67%). During a median follow-up of 2.98 years (range 0.07-15.7 years), medical therapy
was instituted in 20 patients. Ten received beta-blockade in addition to a combination of
digoxin, diuretics and angiotensin converting enzyme inhibitors. Four patients demon-
strated marked response to medical therapy (median EF at presentation 17%, median
EF at last follow-up 45%, duration of therapy range 19-37 months). Overall, stabilization
or improvement was noted in 70% (n=7/10) on beta-blockade. Poor outcome, defined as
transplantation or transplant listing (n=3) or death (n=3) occurred in 27%. Predictors of
listing for transplant and/or death were increased noncompaction:compaction segment
ratio at diagnosis (p=0.01) and increased left ventricular end diastolic dimension (LVED)
at presentation (p=0.05).
Conclusions: IVNC is associated with poor outcome in 27%, which may be predicted by
increased noncompacted segment ratio and/or LVED at presentation. With medical ther-
apy, notably beta-blockade, many can achieve hemodynamic stability or even improved
ventricular function.
1164-130 Chronotropic Stress Enhances the Effects of 
Asynchronous Left Ventricular Activation on Myocardial 
Perfusion in Patients With Idiopathic Dilated 
Cardiomyopathy and Left Bundle Branch Block
Cecilia Marini, Jan Schneider-Eicke, Piero Salvadori, Gianmario Sambuceti, Antonio 
L'Abbate, Danilo Neglia, CNR Institute of Clinical Physiology, Pisa, Italy
Asynchronous left ventricular (LV) activation due to left bundle branch block (LBBB) may
worsen LV function in patients with idiopathic dilated cardiomyopathy (IDC). Aim of this
study was to assess whether this mechanism is enhanced by chronotropic stress and
may affect myocardial blood flow (MBF). To this purpose 17 patients with IDC (NYHA
class I-II, LVEF 36±9%), 9 with and 8 without LBBB, were studied together with 5 normal
subjects. Global and regional MBF values in the septum (S) and in the postero-lateral
wall (PL) were quantitated (ml/min/g) by 13NH3 and positron emission tomography at
rest and during maximal atrial pacing (131±12 bpm). Global and regional EF values at
rest and during pacing were also obtained by equilibrium radionuclide angiography in a
one day protocol. Changes in EF and MBF during stress are presented as stress/rest
ratios. At rest, as compared with normals, patients with and without LBBB had similarly
depressed global LV EF (32±8% and 41±8% vs 58±5%, p<0.001) and comparable global
MBF (0.90±0.22 and 0.78±0.26 vs 0.91±0.17 ml/min/g, ns). During pacing, the regional
EF in S significantly decreased in the LBBB group as compared with normals (0.38±0.36
vs 1.08±0.05, p<0.05) while changes in global EF and regional EF in PL did not signifi-
cantly differ among groups. Global and regional MBF in S increased significantly less
during pacing in patients with LBBB than in normals (1.30±0.22 vs 1.81±0.33 and
1.26±0.21 vs 1.81±0.44, p<0.05) while the regional MBF changes in PL did not differ
between IDC groups.
In conclusion, in patients with IDC and LBBB chronotropic stress enhances the effects of
asynchronous LV activation causing a limitation of regional and global myocardial flow
reserve.
1164-131 Clinical Significance of Lamin A/C Mutations in Dilated 
Cardiomyopathy
Anita M. Arola, Hua Li, Ross Murphy, William J. McKenna, Neil E. Bowles, Jeffrey A. 
Towbin, Baylor College of Medicine, Houston, TX, St. George's Hospital Medical School, 
London, United Kingdom
Background: Dilated cardiomyopathy (DCM), characterized by ventricular dilation and
decreased systolic function, is estimated to be of genetic origin in over 30% of cases. To
date, mutations in 12 different genes, mainly encoding cytoskeletal and sarcomeric pro-
teins, have been associated with familial and sporadic forms of DCM. Mutations in the
gene encoding nuclear envelope protein lamin A/C (LMNA) have been reported in up to
33% of patients with familial DCM, frequently associated with conduction system disease
and variable skeletal muscle involvement. In this study, we evaluated the frequency of
laminopathies in an unselected patient population with DCM.
Methods: LMNA and emerin (EMD) genes were amplified by PCR from the genomic
DNA of 185 unrelated DCM patients and analyzed by denaturing high-performance liquid
chromatography (DHPLC) and sequenced using a Big-Dye Terminator cycle sequencing
system. Institutional review boards approved the study, and all the study subjects gave
their written informed consent.
Results: Three novel mutations in LMNA were identified including a missense mutation
(E291K) in exon 5, a splice site mutation (356+1 G→C) after exon 1, and an insertion
(751insC) in exon 4. Moreover, two previously reported missense mutations (Y45C,
R190W) were found. The phenotype of the patients with LMNA mutations ranged from
pure sporadic DCM without conduction system disease to autosomal dominant DCM with
complete atrio-ventricular block but no signs or symptoms of skeletal muscle disease.
Analysis of EMD identified only one silent mutation.
Conclusions: Potential disease-causing mutations in LMNA were found in only 5 out of
185 (2.7%) patients with DCM. Functional studies to evaluate the significance of these
mutations are ongoing. Genetic defects in EMD do not seem to have a significant role in
the pathogenesis of DCM. In conclusion, defects in LMNA are not common in unselected
patients with DCM, but need to be screened in both pure DCM and DCM with conduction
system disease.
1164-132 Effect of Acute Administration of L-Propionylcarnitine 
on Coronary Flow Velocity Reserve in Patients With 
Systemic Sclerosis
Roberta Montisci, Massimo Ruscazio, Alessandra Vacca, Pietro Garau, Giuseppe 
Passiu, Alessandro Mathieu, Sabino Iliceto, Luigi Meloni, University of Cagliari, Cagliari, 
Italy
Background. Cardiac involvement in systemic sclerosis ( SSc) is controversial but the
primary disorder of microvasculature with diffuse arteriolar and capillary lesions could
precede any fibrosis, thus causing ischemic dysfunction. Previous studies of coronary
flow velocity reserve (CFVR) have demonstrated that CFVR is impaired in patients with
SSc. L-Propionylcarnitine( L-Pc) is a metabolic substance that exerts a beneficial effect
on both microcirculation and myocite function. We tested the hypothesis that CFVR can
be early impaired in patients with SSc without cardiac involvement and whether CFVR
could improve after intravenous administration of L-Pc.
Methods. We studied 11 females patients (6 with diffuse form and 5 with localized form
of SSc) without clinical evidence of heart disease, mean age 54±11 years and 26 control
group patients, matched for age. We evaluated CFVR in the left anterior descending cor-
onary artery (LAD) with contrast Doppler echocardiography during adenosine infusion
(140 µg/Kg/min in 5 minutes), before and after 15 minutes of administration of L-Pc ( 300
mg intravenous in 5 minutes bolus) .
Results: In patients with SSc CFVR was impaired in comparison to the control group
patients ( 2.56 ± 0.54 vs 3.29±0.52, p=0.0005). Furthermore, in patients with SSc after
administration of L-Pc, CFVR increased from 2.56 ± 0.51 to 3.38±0.9, p=0.01. The peak
diastolic velocity in the LAD at rest, before and after L-Pc administration were not differ-
ent (33.8 ±11 vs 28.5±8.6, p=ns).
Conclusion. CFVR is early impaired in patients with SSc without clinical evidence of
heart disease. Acute administration of L-Pc exerts a beneficial effect on microvasculature
in patients with systemic sclerosis. Therefore, its potential after chronic administration
needs to be evaluated.
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1165-103 Effect of Beta-Blocker Therapy on Ventilatory 
Responses in Patients With Heart Failure
Robert Wolk, Bruce D. Johnson, Virend K. Somers, Thomas G. Allison, Ray W. Squires, 
Gerald T. Gau, Lyle J. Olson, Mayo Clinic, Rochester, MN
Background. An augmented ventilatory response to exercise is frequently observed in
patients (pts) with congestive heart failure (CHF). Beta-blocker therapy of CHF improves
hemodynamics, survival and symptoms though it does not improve peak oxygen uptake
(VO2). We hypothesized beta-blocker therapy decreases minute ventilation (VE) in pts
with CHF. Methods. The study group was comprised of 629 CHF pts with LVEF <40%
referred for cardiopulmonary exercise testing (CPET) from 1994 to 2002. Clinical,
echocardiographic, pulmonary function (PFT) and CPET data were reviewed and
recorded. Pts were divided into two subgroups for comparison: those treated with beta-
blockers (n=206) and those not treated with beta-blockers (n=423). Results. Gender,
smoking history, etiology of CHF, other cardioactive medications and PFT findings were
not different for the two subgroups. LVEF was slightly higher (25 vs. 23; p=0.01) with
beta-blocker. At rest, CHF pts on beta-blocker had significantly lower VE (12±4 vs. 14±4
l/min, p<0.001) and increased ventilatory efficiency (42±7 vs. 44±8, p<0.001). VE
remained lower in the beta-blocker subgroup during submaximal and maximal exercise,
by 4 and 6 l/min, respectively (p=0.001). Expired carbon dioxide was not different
between the two subgroups at rest, submaximal or maximal exercise. Ventilatory effi-
ciency was significantly improved at submaximal (32±6 vs. 34±7, p=0.005) and maximal
(34±8 vs. 36±10, p=0.006) exercise with beta-blocker treatment. Peak VO2 was not sig-
nificantly different for the two subgroups (19.1±5.7 vs. 18.6±5.6), though exercise dura-
tion was significantly longer (7.0 vs. 6.5 min; p=0.018) with beta blocker. The differences
in VE and ventilatory efficiency between the two subgroups remained significant by cova-
riate analysis when age, gender, LVEF, peak VO2, body mass index, CHF etiology, smok-
